Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

INGN-201 does not integrate into the host cell genome, demonstrates activity as anticancer vaccine

Jan. 15, 2002

Oncolytic viruses from Cell Genesys show potential in combination therapy of tumors

Jan. 14, 2002

IND for satraplatin transferred to NeoOncoRx

Jan. 14, 2002

Chiron obtains option to Procyon prostate cancer technology

Jan. 14, 2002

Patent coverage obtained by NeoPharm for a NeoLipid antisense compound

Jan. 14, 2002

FDA advisory committee delays review of Bexxar

Jan. 14, 2002

Genta files IND for gallium nitrate in NHL

Jan. 11, 2002

Onyvax initiates phase II trial of Onyvax P in prostate cancer

Jan. 11, 2002

Two phase II trials of Neotrofin initiated in chemotherapy-induced neuropathy

Jan. 10, 2002

DGI BioTechnologies and Novo Nordisk enter collaboration for cancer agents

Jan. 10, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...